Your session is about to expire
← Back to Search
Nemolizumab for Atopic Dermatitis
Study Summary
This trial will test whether a new medication can help improve the effectiveness of vaccinations for people with moderate-to-severe atopic dermatitis.
- Atopic Dermatitis
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 2 trial • 226 Patients • NCT03100344Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have had eczema for at least 2 years.You have a skin condition with a score of 16 or higher on the Eczema Area and Severity Index.You have a history of severe allergic reactions (including anaphylaxis) to any immunoglobulin product or any ingredients in the study drug.You have a history of serious allergic reaction to the vaccine or any of its ingredients like alum, thimerosal, or phenol.You experience severe itching with a score of at least 4 out of 10.
- Group 1: Nemolizumab
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are elderly individuals above the age of 65 able to participate in this clinical experiment?
"This trial is looking to include patients between 12 and 54 years old. There are 101 studies targeting individuals younger than twelve, while 161 look at seniors over 65."
Could you provide a summary of the previous research conducted with Nemolizumab?
"Currently, there are nine studies running on Nemolizumab with six of them in the Phase 3 trial stage. Though most of these trials stem from Regensburg, Missouri, numerous clinical locations across America have data collection efforts for this drug underway (with a total 959 sites)."
How many volunteers are partaking in the research?
"Correct. Information posted on clinicaltrials.gov certifies that this medical trial, which was first uploaded on March 5th 2020, is currently searching for participants. A total of 200 people need to be procured from 61 distinct research facilities."
How many locations are administering this experiment?
"Currently, 61 different medical centres are welcoming prospective participants into this study. These locations span from Miami Lakes and Hialeah to Kew Gardens; you should consider the clinic nearest your residence to reduce travel-related stresses if you choose to participate."
Who is eligible to join the research cohort of this clinical trial?
"To be admitted as a participant, patients should suffer from eczema of the infantile type and fall between 12 to 54 years old. The clinical trial has room for 200 individuals in total."
Are researchers currently recruiting participants for this research study?
"Indeed, according to clinicaltrials.gov, recruitment for this medical research is in full swing since its initial launch on March 5th 2020 and most recent update on July 12th 2022. 200 test subjects are being sought from 61 distinct sites."
Has the FDA granted authorization for Nemolizumab?
"Nemolizumab has been evaluated in a Phase 2 clinical trial, so it is assigned a score of 2 due to the limited evidence backing its safety and lack of efficacy data."
Is this pioneering medical research the first of its kind?
"As of now, 9 on-going clinical trials for Nemolizumab have been identified worldwide, spanning 25 countries and 228 cities. Galderma R&D initiated the first study in 2019 with 750 participants; since then a total of 18328 studies have concluded their Phase 3 approval stage."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger